CME

Program Description:

The experimental antibody-drug conjugate trastuzumab emtansine (T-DM1) has shown significant improvement in progression-free survival (PFS) compared with capecitabine plus lapatinib among patients with HER2+ locally advanced or metastatic breast cancer (MBC) previously treated with a taxane and trastuzumab, according to primary results from the randomized phase 3 EMILIA trial reported at the 2012 Annual Meeting of the American Society of Clinical Oncology.


Continue Reading

INTENDED AUDIENCE:

Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with breast cancer.

Activity Objectives:

After participating in this educational activity, participants should be better able to:

  • Evaluate the efficacy and safety of the experimental antibody-drug conjugate trastuzumab emtansine (T-DM1) among patients with HER2+ locally advanced or metastatic breast cancer.
  • Develop protocols to increase PFS among patients with HER2+ locally advanced or metastatic breast cancer who are inadequately responsive to established treatment protocols.

Click Next to begin the activity.